Champions Oncology Stock Probability of Future Stock Price Finishing Over 8.83
| CSBR Stock | USD 4.33 0.15 3.59% |
Champions |
Champions Oncology Target Price Odds to finish over 8.83
The tendency of Champions Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move over $ 8.83 or more in 90 days |
| 4.33 | 90 days | 8.83 | close to zero percent |
Based on a normal probability distribution, the odds of Champions Oncology to move over $ 8.83 or more in 90 days from now is close to zero percent (This Champions Oncology probability density function shows the probability of Champions Stock to fall within a particular range of prices over 90 days) . Probability of Champions Oncology price to stay between its current price of $ 4.33 and $ 8.83 at the end of the 90-day period is about 65.28 .
Given the investment horizon of 90 days the stock has the beta coefficient of 1.12 suggesting Champions Oncology market returns are sensible to returns on the market. As the market goes up or down, Champions Oncology is expected to follow. Additionally Champions Oncology has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Champions Oncology Price Density |
| Price |
Predictive Modules for Champions Oncology
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Champions Oncology. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Champions Oncology Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Champions Oncology is not an exception. The market had few large corrections towards the Champions Oncology's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Champions Oncology, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Champions Oncology within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.2 | |
β | Beta against Dow Jones | 1.12 | |
σ | Overall volatility | 0.28 | |
Ir | Information ratio | -0.04 |
Champions Oncology Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Champions Oncology for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Champions Oncology can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Champions Oncology had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 50.16 M. Net Loss for the year was (7.28 M) with profit before overhead, payroll, taxes, and interest of 24.34 M. | |
| Champions Oncology currently holds about 8.06 M in cash with (6.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.6. | |
| Champions Oncology has a frail financial position based on the latest SEC disclosures | |
| Roughly 26.0% of the company shares are held by company insiders | |
| Latest headline from MacroaxisInsider: Disposition of 88470 shares by Ackerman Joel of Champions Oncology at 2.1 subject to Rule 16b-3 |
Champions Oncology Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Champions Stock often depends not only on the future outlook of the current and potential Champions Oncology's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Champions Oncology's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 13.5 M | |
| Cash And Short Term Investments | 2.6 M |
Champions Oncology Technical Analysis
Champions Oncology's future price can be derived by breaking down and analyzing its technical indicators over time. Champions Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Champions Oncology. In general, you should focus on analyzing Champions Stock price patterns and their correlations with different microeconomic environments and drivers.
Champions Oncology Predictive Forecast Models
Champions Oncology's time-series forecasting models is one of many Champions Oncology's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Champions Oncology's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Champions Oncology
Checking the ongoing alerts about Champions Oncology for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Champions Oncology help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Champions Oncology had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 50.16 M. Net Loss for the year was (7.28 M) with profit before overhead, payroll, taxes, and interest of 24.34 M. | |
| Champions Oncology currently holds about 8.06 M in cash with (6.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.6. | |
| Champions Oncology has a frail financial position based on the latest SEC disclosures | |
| Roughly 26.0% of the company shares are held by company insiders | |
| Latest headline from MacroaxisInsider: Disposition of 88470 shares by Ackerman Joel of Champions Oncology at 2.1 subject to Rule 16b-3 |
Additional Tools for Champions Stock Analysis
When running Champions Oncology's price analysis, check to measure Champions Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Champions Oncology is operating at the current time. Most of Champions Oncology's value examination focuses on studying past and present price action to predict the probability of Champions Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Champions Oncology's price. Additionally, you may evaluate how the addition of Champions Oncology to your portfolios can decrease your overall portfolio volatility.